FDA Approval of Prostate Cancer Imaging Agent a Milestone for Inventor and Johns Hopkins

FDA Approval of Prostate Cancer Imaging Agent a Milestone for Inventor and Johns Hopkins

The U.S. Food and Drug Administration recently approved the first commercially available positron emission tomography (PET) imaging agent targeting the prostate-specific membrane antigen (PSMA). This represents the culmination of 25 years of work for Martin Pomper, M.D., Ph.D., a professor in the Johns Hopkins Medicine Department of Radiology and Radiological Science. Read more about this innovation here.

Recent Posts
The Importance of Cancer Screening COVID-19 Vaccines for Cancer Patients Computer Program Predicts Tumor Response to Therapy Join the Great American Smokeout! Breastfeeding and COVID-19 Vaccines ‘Fortunate Accident’ May Yield Immunity Weapon Against Antibiotic-Resistant Bacteria COVID-19 vaccine boosters may provide better protection for immunocompromised Genomic Test Helps Estimate Risk of Prostate Cancer Metastasis, Death COVID-19 and Mammograms